Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tofacitinib Citrate

FDA-approved product (tablet, oral), marketed as Tofacitinib Citrate, Xeljanz, Xeljanz Xr.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tofacitinib Citrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psoriatic arthritis
  • Rheumatoid arthritis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Janus-associated kinase (jak) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tofacitinib Citrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tofacitinib Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

    NCT07352566 · start 2026-08-01

    Registered record
    Registry ID
    NCT07352566
    Conditions
    Psoriasis; Atopic Dermatitis
    Interventions
    In situ cutaneous microdevice; Triamcinolone; 5-Fluorouracil; Calcipotriene; Tapinarof; Crisaborole; Tacrolimus; Adalimumab; Etanercept; Certolizumab; Infliximab; Secukinumab; Ixekizumab; Apremilast; Risankizumab; Ustekinumab; Hydroxychloroquine; Methotrexate; Mycophenolate; Azathioprine; Chloroquine; Cyclosporine; Tofacitinib; Deucravacitinib; Dupilumab; Tralokinumab; Guselkumab; Tildrakizumab; Baractinib; Abrocitinib; Upadacitinib; Lebrikizumab; Nemolizumab; Ruxolitinib; Bimekizumab; Roflumilast
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2030-06-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Atopic Dermatitis
    InterventionIn situ cutaneous microdevice; Triamcinolone; 5-Fluorouracil; Calcipotriene +32 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • Topical Use of 2% Tofacitinib for Nail Psoriasis: an Exploratory Clinical Study

    NCT07313072 · start 2026-03

    Registered record
    Registry ID
    NCT07313072
    Conditions
    Nail Psoriasis
    Interventions
    Topical 2% Tofacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-03
    Completion
    2027-03
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNail Psoriasis
    InterventionTopical 2% Tofacitinib
    PhasePhase 2
    Registry statusNot yet recruiting

  • Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

    NCT07138898 · start 2025-12-12

    Registered record
    Registry ID
    NCT07138898
    Conditions
    Rheumatic Disease
    Interventions
    Methotrexate; Sulfasalazine; Hydroxychloroquine; Leflunomide; Azathioprine; Mycophenolate; Cyclosporine; Tacrolimus; Etanercept; Adalimumab; Golimumab; Certolizumab; Infliximab; Rituximab; Belimumab; Tocilizumab; Anakinra; Canakinumab; Abatacept; Secukinumab; Ixekizumab; Bimekizumab; Ustekinumab; Guselkumab; Risankizumab; Tofacitinib; Upadacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-12-12
    Completion
    2028-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatic Disease
    InterventionMethotrexate; Sulfasalazine; Hydroxychloroquine; Leflunomide +23 more
    PhasePhase 2
    Registry statusRecruiting

  • Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus

    NCT07131813 · start 2025-10-10

    Registered record
    Registry ID
    NCT07131813
    Conditions
    Oral Lichen Planus
    Interventions
    Tofacitinib 5 mg BID and Triamcinolone ointment; Placebo and Triamcinolone ointment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-10-10
    Completion
    2027-06-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOral Lichen Planus
    InterventionTofacitinib 5 mg BID and Triamcinolone ointment; Placebo and Triamcinolone ointment
    PhasePhase 4
    Registry statusRecruiting

  • Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis

    NCT06979271 · start 2025-06-01

    Registered record
    Registry ID
    NCT06979271
    Conditions
    Telitacicept; Treatment Compliance; Rheumatoid Arthritis
    Interventions
    Telitacicept Tofacitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-06-01
    Completion
    2027-04-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTelitacicept; Treatment Compliance; Rheumatoid Arthritis
    InterventionTelitacicept Tofacitinib
    PhaseNot recorded
    Registry statusRecruiting

  • Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis

    NCT07008846 · start 2025-05-10

    Registered record
    Registry ID
    NCT07008846
    Conditions
    Moderate to Severe Rheumatoid Arthritis
    Interventions
    To see the efficacy of Upadacitinib, Methotrexate versus Tofacitinib, Methotrexate in moderate to severe Rheumatoid arthritis
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2025-05-10
    Completion
    2026-09-30
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate to Severe Rheumatoid Arthritis
    InterventionTo see the efficacy of Upadacitinib, Methotrexate versus Tofacitinib, Methotrexate in moderate to severe Rheumatoid arthritis
    PhasePhase 3
    Registry statusActive not recruiting

  • Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients

    NCT06465732 · start 2025-01

    Registered record
    Registry ID
    NCT06465732
    Conditions
    Atopic Dermatitis
    Interventions
    Dupilumab; Tofacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2025-01
    Completion
    2026-07
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionDupilumab; Tofacitinib
    PhasePhase 4
    Registry statusUnknown

  • A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients

    NCT06707246 · start 2024-12-15

    Registered record
    Registry ID
    NCT06707246
    Conditions
    Hidradenitis Suppurativa
    Interventions
    Secukinumab 300 MG; Tofacitinib 11mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-12-15
    Completion
    2027-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHidradenitis Suppurativa
    InterventionSecukinumab 300 MG; Tofacitinib 11mg
    PhaseNot applicable
    Registry statusRecruiting

  • Tofacitinib in Patients With Amyotrophic Lateral Sclerosis

    NCT06689982 · start 2024-12-01

    Registered record
    Registry ID
    NCT06689982
    Conditions
    Amyotrophic Lateral Sclerosis
    Interventions
    Tofacitinib tablets
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2024-12-01
    Completion
    2026-06-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis
    InterventionTofacitinib tablets
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS

    NCT06625450 · start 2024-10

    Registered record
    Registry ID
    NCT06625450
    Conditions
    Ulcerative Colitis
    Interventions
    Tofacitinib; Tofacitinib plus mesalamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2024-10
    Completion
    2026-01
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis
    InterventionTofacitinib; Tofacitinib plus mesalamine
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

    NCT06418529 · start 2024-05-15

    Registered record
    Registry ID
    NCT06418529
    Conditions
    Rheumatoid Arthritis
    Interventions
    tofacitinib; tumor necrosis factor inhibitors (TNFi); abatacept; tocilizumab or sarilumab
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-05-15
    Completion
    2024-07-19
    Enrolment
    21,340

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    Interventiontofacitinib; tumor necrosis factor inhibitors (TNFi); abatacept; tocilizumab or sarilumab
    PhaseNot recorded
    Registry statusCompleted

  • Ibd CAncer and seRious Infections in France (I-CARE 2)

    NCT06089590 · start 2024-01-25

    Registered record
    Registry ID
    NCT06089590
    Conditions
    IBD; Ulcerative Colitis; Crohn Disease
    Interventions
    Non-interventional
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-01-25
    Completion
    2031-03-01
    Enrolment
    6,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIBD; Ulcerative Colitis; Crohn Disease
    InterventionNon-interventional
    PhaseNot recorded
    Registry statusRecruiting

  • BT-600 Single and Multiple Ascending Oral Doses in Healthy Adult Subjects

    NCT06275464 · start 2024-01-11

    Registered record
    Registry ID
    NCT06275464
    Conditions
    Healthy
    Interventions
    BT-600; BT-600 Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-01-11
    Completion
    2024-04-23
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBT-600; BT-600 Placebo
    PhasePhase 1
    Registry statusCompleted

  • Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis

    NCT06011343 · start 2023-10-01

    Registered record
    Registry ID
    NCT06011343
    Conditions
    Cutaneous Leishmaniasis, American
    Interventions
    Oral tofacitinib; Parenteral meglumine antimoniate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2023-10-01
    Completion
    2025-07-01
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous Leishmaniasis, American
    InterventionOral tofacitinib; Parenteral meglumine antimoniate
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Therapies for Down Syndrome Regression Disorder

    NCT05662228 · start 2023-06-29

    Registered record
    Registry ID
    NCT05662228
    Conditions
    Down Syndrome; Regression
    Interventions
    Lorazepam; Intravenous immunoglobulin (IVIG); Tofacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-06-29
    Completion
    2026-05-28
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDown Syndrome; Regression
    InterventionLorazepam; Intravenous immunoglobulin (IVIG); Tofacitinib
    PhasePhase 2
    Registry statusCompleted